2月26日晚，华瓷股份(001216)发布公告称，公司于近日收到中国证监会出具的《关于同意湖南华联瓷 业股份有限公司向特定对象发行股票注册的批复》（证监许可[2026]309号），同意公司向特定对象发 行股票的注册申请。本次发行应严格按照报送深圳证券交易所的申报文件和发行方案实施。本批复自同 意注册之日起12个月内有效。 新诺威：拟2.3亿元转让国新汇金30%股份给石药控股 合合信息：2025年净利润同比增长13.39% 2月26日晚，合合信息(688615)发布业绩快报，2025年实现营业收入18.1亿元，同比增长25.83%；实现归 母净利润4.54亿元，同比增长13.39%；基本每股收益为3.24元/股。 生益科技：广新集团及陈仁喜已完成减持计划 2月26日晚，生益科技(600183)发布公告称，截至2026年2月25日，广新集团已通过集中竞价交易方式减 持公司股份合计2429.12万股，占公司总股本的1%。陈仁喜已通过集中竞价交易方式减持公司股份合计 30.08万股，占公司总股本的0.0124%。截至本公告披露日，广新集团及陈仁喜的减持计划已实施完毕。 华瓷股份：向特定对象发行股票申请获同意 2月26 ...

每经AI快讯，福安药业（300194）2月26日公告，全资子公司天衡制药于近日收到国家药品监督管理局 签发的吗啉硝唑化学原料药上市申请批准通知书。吗啉硝唑主要用于治疗由厌氧菌引起的感染性疾病 (如下呼吸道感染、盆腔炎、败血症等)。 ...

格隆汇2月26日丨福安药业(300194.SZ)公布，全资子公司福安药业集团宁波天衡制药有限公司（简 称"天衡制药"）于近日收到国家药品监督管理局签发的化学原料药上市申请批准通知书，原料药名称： 吗啉硝唑。吗啉硝唑主要用于治疗由厌氧菌引起的感染性疾病（如下呼吸道感染、盆腔炎、败血症 等）。 ...

智通财经APP讯，福安药业(300194.SZ)公告，公司全资子公司福安药业集团宁波天衡制药有限公司(简 称"天衡制药")于近日收到国家药品监督管理局签发的化学原料药上市申请批准通知书，原料药名称为 吗啉硝唑。吗啉硝唑主要用于治疗由厌氧菌引起的感染性疾病(如下呼吸道感染、盆腔炎、败血症等)。 ...

福安药业（300194）(300194.SZ)公告，公司全资子公司福安药业集团宁波天衡制药有限公司(简称"天衡 制药")于近日收到国家药品监督管理局签发的化学原料药上市申请批准通知书，原料药名称为吗啉硝 唑。吗啉硝唑主要用于治疗由厌氧菌引起的感染性疾病(如下呼吸道感染、盆腔炎、败血症等)。 ...

特此公告。 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假 记载、误导性陈述或者重大遗漏。 福安药业（集团）股份有限公司（以下简称"公司"）全资子公司福安药业集 团宁波天衡制药有限公司（以下简称"天衡制药"）于近日收到国家药品监督管 理局签发的化学原料药上市申请批准通知书。现将具体情况公告如下： | 原料药名称 | 登记号 | 生产企业 | 包装规格 | 审批结论 | | --- | --- | --- | --- | --- | | 吗啉硝唑 | Y20240000702 | 天衡制药 | 5kg/桶； | 经审查，本品符合药品 注册的有关要求，批准 | | | | | 10kg/桶 | | | | | | | 注册。 | 吗啉硝唑主要用于治疗由厌氧菌引起的感染性疾病（如下呼吸道感染、盆腔 炎、败血症等）。 证券代码：300194 证券简称：福安药业 公告编号：2026-006 福安药业（集团）股份有限公司 关于子公司收到化学原料药上市申请批准通知书的公告 上述原料药产品获得上市批准将可以在国内上市制剂中使用，将进一步丰富 子公司产品线。但受 GMP 合规性检查进度、国家政策、市场环境 ...

近7个交易日，福安药业股价震荡下行，累计跌幅1.12%，区间振幅4.20%。截至2月13日收盘，股价报 4.40元，当日持平，换手率0.50%，成交金额2135万元；主力资金呈净流出态势，2月12日单日净流出 1301.04万元，占成交额20.43%。技术面上，股价目前位于20日布林带下轨附近，MACD指标显示短期 趋势偏弱。同期医药生物板块下跌0.32%，公司股价表现略弱于行业平均水平。 经济观察网福安药业（300194）子公司共计28个药品品种在国家组织集采药品协议期满品种接续采购中 拟中选，涉及右美托咪定、阿哌沙班、喹硫平等品种，涵盖抗感染、精神类、麻醉类等领域。这些产品 2024年度合计销售额约6.80亿元，占公司营收28.43%；2025年前三季度合计销售额约3.29亿元，占营收 25.05%，采购周期至2028年12月31日。此次接续采购有助于稳定公司集采基本盘，但需关注价格下降 对毛利率的潜在压力。 股票近期走势 以上内容基于公开资料整理，不构成投资建议。 ...

（文章来源：证券日报） 证券日报网讯 2月12日，福安药业在互动平台回答投资者提问时表示，截至2月10日，公司股东户数为 38647户。 ...

Group 1 - Fuda Alloy's controlling shareholder Wang Dawu plans to reduce his stake by up to 3% of the company's total shares, amounting to a maximum of 406.34 million shares, due to personal funding needs [1] - ST Songfa's subsidiary signed contracts for the construction of 17 vessels, with a total contract value between 1.6 billion to 1.8 billion USD [2] - Pairui Co. signed a technical cooperation agreement with a university to develop large-capacity power semiconductor devices and related power electronic modules, effective for three years [3] Group 2 - Shuangliang Energy indirectly participates in commercial aerospace projects, supplying heat exchangers for SpaceX's fuel production system, with orders totaling approximately 1.39 million CNY [4] - Hangya Technology plans to issue convertible bonds to raise up to 600 million CNY for various projects, including an intelligent manufacturing base in Malaysia [5] - Yuhua Development is publicly selling assets with a base price of 251 million CNY for residential properties [6] Group 3 - Penghui Energy plans to invest 2.1 billion CNY in a new battery production project in Zhengyang County, Henan Province, focusing on high-performance battery products [7] - Haige Communication's shareholder Yang Haizhou intends to reduce his stake by up to 0.1624% of the company's total shares [8] - Yaoshi Technology's controlling shareholder pledged 5.13% of shares to repay loans, with a pledge period from February 10, 2026, to February 2, 2027 [9][10] Group 4 - Hanyu Pharmaceutical received FDA approval for its drug Acetate Glatiramer Injection, used for treating relapsing multiple sclerosis [11] - Baiyao Tai's GoliMab Injection received EMA approval for various indications, including rheumatoid arthritis and ulcerative colitis [12] - Jiangxi Tungsten Equipment plans to issue A-shares to raise up to 1.882 billion CNY for acquisitions [13] Group 5 - Hesong New Materials expects to recognize asset impairment provisions between 23.6 million to 28.5 million CNY for 2025 [14] - ST Meichen's subsidiary is involved in two major lawsuits with a total amount of approximately 31.9 million CNY [15] - China Coal Energy reported a 7.3% year-on-year decline in coal sales for January 2026, with total sales of 20.05 million tons [16] Group 6 - Yida Co. plans to adjust its epoxy propylene derivative project, reducing the total investment from 845 million CNY to 642 million CNY [17] - Fosun Pharma's subsidiary received approval for a clinical trial of HLX15-SC for multiple myeloma treatment [18][19] - Yinfeng Communication's board members and executives have terminated their share reduction plan [20] Group 7 - Huazhong High-tech has waived its preferential purchase rights for a fund, extending the investment period from three to four years [21] - Warner Pharmaceuticals plans to participate in a national drug procurement program, with expected sales of 176 million CNY [22] - Changling Hydraulic announced a tender offer to acquire 12% of its shares at a price of 35.82 CNY per share [23] Group 8 - ST Chuan Zhi's stock may face delisting due to financial data falling below regulatory thresholds [24] - Tian Pharmaceutical and its subsidiaries are participating in a national drug procurement program, with expected sales of 323 million CNY [25] - China Metallurgical Group signed new contracts worth 73.65 billion CNY in January 2026 [26] Group 9 - Torus plans to invest 21.2 million CNY in a venture capital fund focused on artificial intelligence [27] - Shangwei Co. received a government subsidy of 1.764 million CNY, representing 10.79% of its net profit for 2024 [28] - Hanghua Co. reported a 21.97% decline in net profit for 2025, with total revenue of 1.249 billion CNY [29] Group 10 - Huaxia Bank reported a 1.72% decline in net profit for 2025, with total revenue of 91.914 billion CNY [30] - Guotou Fengle plans to transfer 51% of its stake in Hubei Fengle Ecological Fertilizer to optimize management [31] - Huaru Technology is co-investing in a fund with a total commitment of 20 million CNY [32] Group 11 - Jindike reported a loss of 173 million CNY for 2025, despite a 40.13% increase in revenue [33] - Zhenong Co. announced a 0.52% increase in shares held by a major shareholder [34] - Maike Audi plans to recognize asset impairment provisions of approximately 52.55 million CNY [35] Group 12 - Fuan Pharmaceutical's subsidiary is expected to be selected for a national drug procurement program, with projected sales of 680 million CNY [36] - Rundu Co. is participating in a national drug procurement program, with some products expected to be selected [37] - Changqing Co. has postponed its large-scale die-casting project to March 2027 due to customer requirements [38] Group 13 - Pan Asia Micro透 received a patent for a graphene-based automotive headlight defogging device [39] - Luan An Huan Neng reported a 17.1% increase in raw coal production for January 2026, totaling 5 million tons [40] - Guangji Pharmaceutical received a drug registration certificate for Mecobalamin Tablets [41] Group 14 - Ruifeng New Materials announced the resignation of its deputy general manager for personal reasons [42] - Zhiguang Electric's subsidiary signed a procurement contract for energy storage equipment worth 210.4 million CNY [43] - Youyan Powder Materials reported a 19.41% increase in net profit for 2025 [44] Group 15 - Jincheng reported a 22.2% increase in net profit for 2025, with total revenue of 253 million CNY [46]

格隆汇2月12日丨福安药业(300194.SZ)公布，全资子公司福安药业集团庆余堂制药有限公司、福安药业 集团宁波天衡制药有限公司、福安药业集团烟台只楚药业有限公司、福安药业集团湖北人民制药有限公 司于近日参与了国家组织集采药品1-8批协议期满品种接续采购的投标工作，根据国家组织集采药品协 议期满品种接续采购办公室（简称"接续采购办公室"）于2026年2月10日发布的《国家组织集采药品协 议期满品种接续采购拟中选结果表（LC-YPJX-2026-1）》显示，公司子公司共计28个药品品种拟中选 本次接续采购。 ...